18 Jan Mammoth Biosciences
Peter Nell, Ph.D., Chief Business Officer and Head of Therapeutics
April 21 | 2:00pm | Gaudi 2 Ballroom
Mammoth Biosciences is harnessing the diversity of nature to power the next generation of CRISPR products. With a distinguished team, including co-founder and Nobel Laureate Jennifer Doudna, Mammoth is discovering and optimizing novel CRISPR systems enabling the full potential to read and write the code of life. Mammoth’s efforts are focused on CRISPR-based diagnostics and on differentiated gene editing-based therapeutics benefiting from our proprietary and ultra-small CRISPR systems with unique characteristics. The company is establishing a pipeline of partnered and in-house programs to advance both disease detection and treatment. In October 2021, Mammoth signed a partnership with Vertex Pharmaceuticals exploring potential cures for two undisclosed in vivo indications with high medical need.